Shots:

• Chugai gets exclusive development and commercializing rights for AT-527 in Japan
• Earlier- Roche and Atea collaborated to jointly develop AT-527. If approved- Atea to distribute AT-527 in the US and Roche will be responsible for global manufacturing and distribution outside the US
• AT-527 is an investigational- oral- purine nucleotide prodrug- currently being evaluated in a P-II study in patients with moderate COVID-19 requiring hospitalization and patients with mild to mod. COVID-19 who are not hospitalized. A P-III study is expected to start in the H1’21

 ­ Ref: Chugai | Image: Roche